PA8661201A1 - 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2 - Google Patents
2-fenil-indoles como antagonistas del receptor de la prostaglandina d2Info
- Publication number
- PA8661201A1 PA8661201A1 PA20068661201A PA8661201A PA8661201A1 PA 8661201 A1 PA8661201 A1 PA 8661201A1 PA 20068661201 A PA20068661201 A PA 20068661201A PA 8661201 A PA8661201 A PA 8661201A PA 8661201 A1 PA8661201 A1 PA 8661201A1
- Authority
- PA
- Panama
- Prior art keywords
- pharmaceutically acceptable
- diseases
- inflammation
- allergic
- patient
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
LA PRESENTE INVENCION SE REFIERE A UN COMPUESTO DE LA FORMULA (XVI) EN LA QUE R, R2, R4, R5, R6, R7 Y N SON COMO SE DEFINEN AQUI, O UNA DE SUS SALES, HIDRATOS O SOLVATOS FARMACEUTICAMENTE ACEPTABLES, UNO DE SUS PROFARMACOS FARMACEUTICAMENTE ACEPTABLES, O UNA SAL, HIDRATO O MSOLVATO DEL PROFARMACO FARMACEUTICAMENTE ACEPTABLE, UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DE UNO O MAS COMPUESTOS SEGUN LA FORMULA (XVI) EN MEZCLA CON UN VEHICULO FARMACEUTICAMENTE ACEPTABLE, UN METODO PARA TRATAR A UN PACIENTE QUE SUFRE UN TRASTORNO MEDIADO POR LA PGD2 INCLUYENDO, PERO SIN LIMITARSE A ELLAS, ENFERMEDADES ALERGICAS (TALES COMO RINITIS ALERGICA, CONJUNTIVITIS ALERGICA, DERMATITIS ATOPICA, ASMA BRONQUIAL Y ALERGIA A LOS ALIMENTOS, MASTOCITOSIS SISTEMICA, TRASTORNOS ACOMPAÑADOS DE LA ACTIVACION SISTEMICA DE LOS MASTOCITOS, SHOK ANAFILACTICO, BRONCOCONSTRICCION, BRONQUITIS, URTICARIA, ECZEMA, ENFERMEDADES ACOMPAÑADAS DE PRURITO (TALES COMO DERMATITIS ATOPICA Y URTICARIA), ENFERMEDADES (TALES COMO CATARATAS, DESPRENDIMIENTO DE RETINA, INFLAMACION, INFECCION Y TRASTORNOS DEL SUEÑO) QUE SE GENERAN DE FORMA SECUNDARIA COMO RESULTADO DE LA CONDUCTA ACOMPAÑADAS DE PRURITO (TALES COMO ESCARIFICACIONES Y CONTUSIONES), INFLAMACION, ENFERMEDADES PULMONARES OBSTRUCTIVAS CRONICAS, LESIONES POR REPERFUSION ISQUEMICA, ACCIDENTE CEREBROVASCULAR, ARTRITIS REUMATOIDE CRONICA, PLEURESIA, COLITIS ULCEROSA Y SIMILARES, ADMINISTRANDO A DICHO PACIENTE UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DE UN COMPUESTO SEGUN LA FORMULA (XVI).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64730705P | 2005-01-26 | 2005-01-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8661201A1 true PA8661201A1 (es) | 2006-09-08 |
Family
ID=36282872
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA20068661201A PA8661201A1 (es) | 2005-01-26 | 2006-01-26 | 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2 |
Country Status (25)
Country | Link |
---|---|
US (1) | US20070265278A1 (es) |
EP (1) | EP1844011A1 (es) |
JP (1) | JP2008528606A (es) |
KR (1) | KR20070110277A (es) |
CN (1) | CN101146770A (es) |
AR (1) | AR054726A1 (es) |
AU (1) | AU2006209213A1 (es) |
BR (1) | BRPI0607079A2 (es) |
CA (1) | CA2595728A1 (es) |
CR (1) | CR9214A (es) |
DO (1) | DOP2006000016A (es) |
GT (1) | GT200600030A (es) |
IL (1) | IL184816A0 (es) |
MA (1) | MA29259B1 (es) |
MX (1) | MX2007008277A (es) |
NO (1) | NO20074336L (es) |
PA (1) | PA8661201A1 (es) |
PE (1) | PE20060878A1 (es) |
RU (1) | RU2007132166A (es) |
SG (1) | SG158918A1 (es) |
TN (1) | TNSN07251A1 (es) |
TW (1) | TW200639151A (es) |
UY (1) | UY29346A1 (es) |
WO (1) | WO2006081343A1 (es) |
ZA (1) | ZA200705449B (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090039735A (ko) * | 2006-07-25 | 2009-04-22 | 사노피-아벤티스 | 프로스타글란딘 d2 수용체 길항제로서의 2-페닐-인돌 |
CN101500996B (zh) | 2006-08-07 | 2012-07-04 | 埃科特莱茵药品有限公司 | (3-胺基-1,2,3,4-四氢-9h-咔唑-9-基)-乙酸衍生物 |
WO2008061006A1 (en) * | 2006-11-10 | 2008-05-22 | Wyeth | Substituted indan-2-yl, tetrahydronaphthalen-2-yl, or dihydr0-2h-chr0men-3-yl arylsulfonamides and methods of their use |
WO2009061730A2 (en) * | 2007-11-05 | 2009-05-14 | Array Biopharma Inc. | 4-heteroaryl-substituted phenoxyphenylacetic acid |
RU2562255C2 (ru) | 2010-03-22 | 2015-09-10 | Актелион Фармасьютиклз Лтд | Производные 3-(гетероариламино)-1,2,3,4-тетрагидро-9н-карбазола и их применение в качестве модуляторов рецепторов простагландина d2 |
US8722719B2 (en) * | 2010-10-06 | 2014-05-13 | Kureha Corporation | Amine compound and use for same |
US9096595B2 (en) | 2011-04-14 | 2015-08-04 | Actelion Pharmaceuticals Ltd | 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin D2 receptor modulators |
EP2548863A1 (en) * | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists. |
WO2013047725A1 (ja) * | 2011-09-29 | 2013-04-04 | 塩野義製薬株式会社 | Pgd2拮抗剤及びヒスタミン拮抗剤からなるアレルギー性鼻炎治療用医薬 |
EP2794563B1 (en) | 2011-12-21 | 2017-02-22 | Actelion Pharmaceuticals Ltd | Heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
EP2885307A1 (en) | 2012-07-05 | 2015-06-24 | Actelion Pharmaceuticals Ltd. | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
WO2014066568A1 (en) | 2012-10-24 | 2014-05-01 | Winthrop-University Hospital | Non-invasive biomarker to identify subjects at risk of preterm delivery |
JP6168520B2 (ja) * | 2013-09-17 | 2017-07-26 | 国立大学法人 千葉大学 | インドール化合物、dpプロスタノイド受容体アンタゴニスト、それを用いた薬剤、及びdpプロスタノイド受容体アンタゴニストの使用。 |
JP2015089886A (ja) * | 2013-11-06 | 2015-05-11 | 国立大学法人名古屋大学 | 嵩高い置換基を有する化合物を用いた植物成長調整剤 |
WO2015140684A1 (en) | 2014-03-17 | 2015-09-24 | Actelion Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
CN106103437A (zh) | 2014-03-18 | 2016-11-09 | 埃科特莱茵药品有限公司 | 氮杂吲哚乙酸衍生物及其作为前列腺素d2受体调节剂的用途 |
EP3350179B1 (en) | 2015-09-15 | 2021-01-13 | Idorsia Pharmaceuticals Ltd | Crystalline forms |
SG11202002065VA (en) | 2017-09-13 | 2020-04-29 | Progenity Inc | Preeclampsia biomarkers and related systems and methods |
EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS |
CN113173877B (zh) * | 2020-10-30 | 2023-10-27 | 江西师范大学 | 吲哚乙酰基亚氨基砜系列化合物及其制备方法 |
CN115925606B (zh) * | 2023-01-05 | 2023-10-13 | 宁夏医科大学 | 一种5-(3-(磺酰胺基)苯基)-1h-吡咯-2-羧酸衍生物及其制备方法和应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0639567A1 (en) * | 1992-05-08 | 1995-02-22 | Otsuka Pharmaceutical Factory, Inc. | Indole derivative |
FR2751966B1 (fr) * | 1996-08-01 | 1998-10-30 | Union Pharma Scient Appl | Nouveaux derives 1,2-diarylindoles, leurs procedes de preparation, et leurs utilisations en therapeutique |
US6500853B1 (en) * | 1998-02-28 | 2002-12-31 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
DE10204462A1 (de) * | 2002-02-05 | 2003-08-07 | Boehringer Ingelheim Pharma | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse |
JP2004024655A (ja) * | 2002-06-27 | 2004-01-29 | Aruze Corp | 遊技機 |
EP1600440A1 (en) * | 2003-03-06 | 2005-11-30 | Ono Pharmaceutical Co., Ltd. | Indole derivative compounds and drugs containing the compounds as the active ingredient |
SE0301569D0 (sv) * | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
SE0303180D0 (sv) * | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
WO2006019831A1 (en) * | 2004-07-14 | 2006-02-23 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
US7868037B2 (en) * | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
-
2006
- 2006-01-20 DO DO2006000016A patent/DOP2006000016A/es unknown
- 2006-01-24 PE PE2006000105A patent/PE20060878A1/es not_active Application Discontinuation
- 2006-01-25 GT GT200600030A patent/GT200600030A/es unknown
- 2006-01-25 CA CA002595728A patent/CA2595728A1/en not_active Abandoned
- 2006-01-25 AU AU2006209213A patent/AU2006209213A1/en not_active Abandoned
- 2006-01-25 JP JP2007553221A patent/JP2008528606A/ja active Pending
- 2006-01-25 CN CNA2006800097886A patent/CN101146770A/zh active Pending
- 2006-01-25 AR ARP060100278A patent/AR054726A1/es not_active Application Discontinuation
- 2006-01-25 RU RU2007132166/04A patent/RU2007132166A/ru not_active Application Discontinuation
- 2006-01-25 BR BRPI0607079-5A patent/BRPI0607079A2/pt not_active IP Right Cessation
- 2006-01-25 KR KR1020077017292A patent/KR20070110277A/ko not_active Application Discontinuation
- 2006-01-25 WO PCT/US2006/002736 patent/WO2006081343A1/en active Application Filing
- 2006-01-25 SG SG201000540-3A patent/SG158918A1/en unknown
- 2006-01-25 MX MX2007008277A patent/MX2007008277A/es not_active Application Discontinuation
- 2006-01-25 EP EP06719551A patent/EP1844011A1/en not_active Withdrawn
- 2006-01-26 UY UY29346A patent/UY29346A1/es unknown
- 2006-01-26 PA PA20068661201A patent/PA8661201A1/es unknown
- 2006-01-26 TW TW095102967A patent/TW200639151A/zh unknown
-
2007
- 2007-06-28 CR CR9214A patent/CR9214A/es not_active Application Discontinuation
- 2007-07-03 TN TNP2007000251A patent/TNSN07251A1/en unknown
- 2007-07-04 ZA ZA200705449A patent/ZA200705449B/xx unknown
- 2007-07-24 IL IL184816A patent/IL184816A0/en unknown
- 2007-07-25 US US11/782,890 patent/US20070265278A1/en not_active Abandoned
- 2007-08-17 MA MA30150A patent/MA29259B1/fr unknown
- 2007-08-24 NO NO20074336A patent/NO20074336L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20070265278A1 (en) | 2007-11-15 |
CA2595728A1 (en) | 2006-08-03 |
PE20060878A1 (es) | 2006-10-18 |
ZA200705449B (en) | 2009-01-28 |
UY29346A1 (es) | 2006-08-31 |
JP2008528606A (ja) | 2008-07-31 |
TNSN07251A1 (en) | 2008-12-31 |
NO20074336L (no) | 2007-10-23 |
CR9214A (es) | 2007-11-23 |
AR054726A1 (es) | 2007-07-11 |
EP1844011A1 (en) | 2007-10-17 |
BRPI0607079A2 (pt) | 2009-08-04 |
AU2006209213A1 (en) | 2006-08-03 |
GT200600030A (es) | 2006-09-27 |
MX2007008277A (es) | 2007-09-07 |
TW200639151A (en) | 2006-11-16 |
MA29259B1 (fr) | 2008-02-01 |
IL184816A0 (en) | 2007-12-03 |
RU2007132166A (ru) | 2009-03-10 |
KR20070110277A (ko) | 2007-11-16 |
CN101146770A (zh) | 2008-03-19 |
SG158918A1 (en) | 2010-02-26 |
WO2006081343A1 (en) | 2006-08-03 |
DOP2006000016A (es) | 2006-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8661201A1 (es) | 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2 | |
DOP2019000168A (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
MD20140059A2 (en) | Substituted 4-phenyl-pyridines for the treatment of NK-1 receptor related diseases | |
CO7310522A2 (es) | Compuestos de bis (fluoroalquil)-1,4-benzodiazepinona como inhibidores de notch | |
CY1120258T1 (el) | Ενωσεις ετεροδικυκλο-υποκατεστημενης-[1,2,4]τριαζολο [1,5-c]κιναζολιν-5-αμινης καταλληλες για αγωγη ή προληψη διαταραχων του κεντρικου νευρικου συστηματος | |
ECSP14027564A (es) | Agentes para tratar trastornos que implican la modulación de receptores de rianodina | |
DOP2018000204A (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
GT201300324A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a | |
CO6771446A2 (es) | Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona | |
DOP2016000281A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
GT201500030A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
ECSP14013217A (es) | 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk. | |
CR20190073A (es) | FORMAS DE DOSIFICACIÓN DE RUXOLITINIB DE LIBERACIÓN SOTENIDA (Divisional 2015-265) | |
NI201400014A (es) | Inhibidores de pde10 de pirimidina | |
PE20150669A1 (es) | Derivados de benzamida para la inhibicion de la actividad de abl1, abl2 y bcr-abl1 | |
AR065622A1 (es) | Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona | |
CO6290683A2 (es) | Compuestos de pirido imidazolinas heterociclicas y sus composiciones como inhibidores de c-met | |
CO7280468A2 (es) | Antagonistas del receptor de 5-ht3 | |
UY32574A (es) | Antagonistas del receptor cxcr3 | |
CO2017003321A2 (es) | Inhibidores de gingipaina de lisina | |
UY37947A (es) | Amidas de imidazopiridina sustituidas y su uso | |
CO7380758A2 (es) | Derivados de la 2-(morfolin-4-il)-3-(1-amino-3-trifluorometil-piridin-4-il)-5-(oxazol-3-il-2-ona)-pirimidina, activos como inhibidores pi3k mtor, composiciones farmacéuticas del mismo, y sus métodos de fabricación | |
UY32562A (es) | Pirimidinas sustituidas por imidazol 724 | |
CL2012002570A1 (es) | Compuestos derivados de ácido 2-(3heteroaril-amino-1,2,3,4-tetrahidro-9h-carbazol)-acético, composicion farnaceutica que los comprende, y su uso como medicamentos, en la profilaxis y/o el tratamiento de patologias mediadas por la modulacion de receptores de prostaglandinas d2, como trastornos alergicos o inmunitarios. | |
CL2009001759A1 (es) | Compuesto (4-(5-aminometil-2-fluorofenil)piperidin-1-il)(7-fluoro-1(2-metoxietil)-4-trifluorometoxi-1h-indol-3-il)metanona; forma cristalina a de la sal benzoato; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades inflamatorias, tales como epoc, alergia,dermatitis atopica, entre otras. |